![]() ![]() In one analysis, among the top 200 best-selling drugs, 90% of brand-name products and no generic products had a coupon available in 2014 among brand-name drugs with a coupon, almost half had a generic competitor. Offset programs are also distinct from free samples distributed through clinicians’ offices. These programs are distinct from foundation-sponsored patient assistance programs, which are administered separately from manufacturers and typically provide free drugs or reimburse copayments after transactions have been adjudicated. Pharmaceutical manufacturers have developed strategies to maintain market share in response to these benefit-design tools, including offering patients prescription drug coupons, vouchers, and other types of copayment “offsets.”Ĭopayment offsets provide out-of-pocket cost discounts or free product at the point of sale (eg, pharmacy). 1, 2, 3 The increasing cost of prescription drugs has prompted health plans to increase the use of benefit designs, such as cost sharing and utilization management, to direct enrollees to lower-priced products, with the goal of curtailing drug spending. Millions of US citizens pay out-of-pocket prescription drug costs, with up to one-third reporting cost-related nonadherence during the previous year. The statements, findings, conclusions, views, and opinions contained and expressed herein are not necessarily those of IQVIA Inc or any of its affiliated or subsidiary entities. Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study collection, management, analysis, and interpretation of the data preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.ĭisclaimer: The statements, findings, conclusions, views, and opinions contained and expressed in this article are based in part on data obtained under license from the following IQVIA information service(s): Formulary Impact Analyzer, IQVIA. No other disclosures were reported.įunding/Support: This work was supported in part by Arnold Ventures. ![]() Dr Alexander reported serving as past Chair of the US Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee serving as a paid adviser to IQVIA being a co–founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation and being a member of OptumRx’s National P&T Committee. Statistical analysis: Sen, Kang, Rashidi, Ganguli.Īdministrative, technical, or material support: Kang, Rashidi, Alexander.Ĭonflict of Interest Disclosures: All authors reported receiving grants from Arnold Ventures during the conduct of the study. Caleb Alexander, MD, MS, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, W6035, Baltimore, MD 21205 ( Contributions: Dr Sen and Ms Kang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.Ĭoncept and design: Sen, Anderson, Alexander.Īcquisition, analysis, or interpretation of data: Sen, Kang, Rashidi, Ganguli, Alexander.ĭrafting of the manuscript: Sen, Rashidi, Anderson, Alexander.Ĭritical revision of the manuscript for important intellectual content: Sen, Kang, Rashidi, Ganguli, Alexander. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |